Sorrento Therapeutics Inc (SRNE)

[dia76ca]

Have you ever looked at the potential sales in Sorrento's COVID, PAIN and CANCER and INFLAMMATION portfolios two or three years from now? Make your own judgements. Here are mine.

1. COVID
COVISTIX, COVIDROPS, COVIMSC etc... and second generation booster vaccines and anti-virals. Revenues begin this year. Annual Sales of at least $10 Billion.

2. PAIN
SP-102, SP-103, SP-104 target huge sciatica, back pain and Covid long hauler markets. RTX in Cancer and Arthritic pain. Revenues begin in 2H of 2022. Annual Sales of at least $15 Billion.

3. CANCER + INFLAMMATION
ABIVERTINIB in NSCLC and other solid tumours, and against cytokine storm, lupus and MS. At least 12 ADNAB(Mayo Clinic) indications and dozens of CAR-T, DAR-T and other drugs. Sofusa lymphatic drug delivery system. Revenues begin in 2022. Annual Sales of at least $20 Billion.

Potential market Cap? Multi-Billions!